Newtopia Reports Second Quarter 2024 Financial Results
Newtopia is well-positioned to grow and create value in key market opportunities at the forefront of global healthcare:
- Growth of GLP-1s: Our engagement expertise provides unique ability to facilitate sustainable health outcomes and demonstrable ROI to GLP-1 sponsors
- Rise of Health AI: Our unique data sets and capabilities will enrich and accelerate progress of next-gen clinical discovery platforms
- Commercial and Community Care-Delivery: We see continued expansion with our market-leading employer, provider and provincial innovation partners
Second Quarter 2024 Financial Highlights (vs. Q2 2023):
- Revenue of
$1.6 million , as compared to$2.4 million - Gross Profit margin of 48%, as compared to 50%
- Opex reduction of 18% year over year
"Over the last eleven years Newtopia's habit change solution has repeatedly proven our unique ability to produce industry leading patient engagement and to cultivate in our users the healthy habits that can prevent, slow and even reverse chronic metabolic disease. We've positioned ourselves at the forefront of healthcare developments, strengthened underlying operations, and evolved with value-based industry needs. As the economy strengthens Newtopia will be best positioned to support the innovative payers looking to drive proven health outcomes."
"Beginning with our industry-first randomized, controlled clinical trial between 2013-2016 and extending to the Fortune 500 employers that have adopted our solution, Newtopia has consistently delivered weight loss and reductions in A1C in participants that are not only clinically significant, but also sustainable over time. This has translated into meaningful cost-savings for our employer-partners and program sponsors and improved the health and well-being for the more than 100,000 individuals whom we have served, irrespective of their setting, geography, healthy equity or socio-economic status. Most recently, Newtopia reported six-month outcomes from its trial with Heartland Whole Health Institute in which we delivered our best-ever engagement rates and weight loss outcomes in both provider and employer environments."
"On the strength of this foundation, we are pursuing three distinct and significant opportunities to accelerate Newtopia's growth including: (1) expanding our key innovation partnerships with providers, employers and provincial payers; (2) combining Newtopia's proven habit change platform with GLP-1 drugs for obesity and type 2 diabetes; and (3) partnering with health AI and clinical discovery innovators to improve our collective ability to deliver best in breed outcomes that prevent, reverse and slow chronic disease", said
Second Quarter 2024 Financial Results
Revenue for the three months ended
Gross profit for the second quarter 2024 totaled
Operating expenses for the three months ended
The Company ended the second quarter 2024 with
2024 Outlook
Despite a challenging macro environment, the Company remains bullish regarding its strategic fit within the broader healthcare industry. Newtopia will continue to execute on its pipeline to return to EBITDA positive.
Conference Call
The Company will host a conference call on August 8th at 5 p.m. Eastern Time to discuss the second quarter 2024 results in further detail. To access the conference call, please dial (800) 717-1738 (
A replay of the conference call will be available through
About Newtopia
Newtopia is a personalized whole health platform helping people create positive lifelong habits that prevent, slow, or reverse chronic disease while reducing healthcare costs. The platform leverages genetic, social and behavioral insights to create individualized prevention programs with a focus on metabolic disease, diabetes, mental health challenges, hypertension, weight management and musculoskeletal disorders. With a person-centered approach that combines virtual care, digital tools, connected devices and actionable data science, Newtopia delivers sustainable clinical and financial outcomes. Newtopia serves some of the largest nationwide employers and health plans and is currently listed in
Forward Looking Statements
This news release contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, and forward looking statements, within the meaning of applicable
For more information on these risks please see the "Risk Factors" in Newtopia's final long-form prospectus dated
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Key Financial Measures and Schedule of Non-GAAP Reconciliations
Unaudited Gross Profit Information- including
amortization
Three Months Ended | Six Months Ended | |||||||
2024 | 2023 | 2024 | 2023 | |||||
$ | $ | $ | $ | |||||
Revenue | 1,568,970 | 2,357,034 | 3,382,970 | 5,005,691 | ||||
Cost of revenue | (808,397) | (1,184,993) | (1,707,793) | (2,460,675) | ||||
Gross profit | 760,573 | 1,172,041 | 1,675,177 | 2,545,016 | ||||
Gross profit margin | 48 % | 50 % | 50 % | 51 % | ||||
Reconciliation of Total Operating Expenses to Adjusted Operating Expenses
Three Months Ended | Six Months Ended | ||||||
2024 | 2023 | 2024 | 2023 | ||||
$ | $ | $ | $ | ||||
Total expenses | 1,936,354 | 2,403,354 | 4,060,329 | 5,149,156 | |||
Add (Subtract) | |||||||
Share-based compensation | (67,425) | (215,013) | (141,090) | (308,303) | |||
Depreciation of property and equipment | (735) | (2,030) | (1,470) | (3,579) | |||
Interest and accretion expense | (275,963) | (177,728) | (543,324) | (347,423) | |||
Interest on lease obligations | - | (8,973) | - | (21,563) | |||
Finance charges | (110,664) | (122,318) | (239,689) | (231,966) | |||
Amortization of deferred finance charges | (27,887) | (33,975) | (85,900) | (67,790) | |||
Foreign exchange gain (loss) | 34,057 | (35,821) | 30,749 | (54,093) | |||
(Loss) Gain on settlement of related party payable | - | 7,203 | (9,797) | 7,203 | |||
Adjusted operating expenses | 1,487,737 | 1,814,699 | 3,069,808 | 4,121,642 | |||
Unaudited Adjusted Operating Loss
Three Months Ended | Six Months Ended | |||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||
$ | $ | $ | $ | |||||||||||
Gross profit | 760,573 | 1,172,041 | 1,675,177 | 2,545,016 | ||||||||||
Add back amortization of intangible asset | - | 206,514 | - | 413,028 | ||||||||||
Adjusted gross profit | 760,573 | 1,378,555 | 1,675,177 | 2,958,044 | ||||||||||
Adjusted operating expenses | (1,487,737) | (1,814,699) | (3,069,808) | (4,121,642) | ||||||||||
Adjusted operating loss | (727,164) | (436,144) | (1,394,631) | (1,163,598) | ||||||||||
Newtopia Inc.
Condensed Interim Consolidated Statements of Financial Position (Unaudited)
As at
(Expressed in Canadian Dollars)
2024 | 2023 | |||
$ | $ | |||
Assets | ||||
Current assets | ||||
Cash | 519,927 | 387,339 | ||
Trade and other receivables | 430,176 | 1,400,959 | ||
Contract assets | 4,044 | 259,072 | ||
Prepaid expenses and deposits | 254,018 | 101,043 | ||
Inventories | 156,268 | 115,232 | ||
Deferred costs | 25,233 | 64,583 | ||
1,389,666 | 2,328,228 | |||
Property and equipment | 3,195 | 4,665 | ||
1,392,861 | 2,332,893 | |||
Liabilities | ||||
Current liabilities | ||||
Trade and other payables | 2,223,873 | 1,825,356 | ||
Credit facility | 4,745,798 | 4,767,006 | ||
Deferred revenue | - | 48,185 | ||
Debentures | 3,996,311 | 3,723,530 | ||
10,965,982 | 10,364,077 | |||
Debentures | 1,438,364 | 1,387,476 | ||
12,404,346 | 11,751,553 | |||
Shareholders' Equity (Deficit) | ||||
Common shares | 49,754,858 | 49,404,596 | ||
Contributed surplus | 14,593,253 | 14,151,188 | ||
Deficit | (75,359,596) | (72,974,444) | ||
(11,011,485) | (9,418,660) | |||
1,392,861 | 2,332,893 | |||
Newtopia Inc.
Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Unaudited)
Six Months Ended
(Expressed in Canadian Dollars)
2024 | 2023 | ||
$ | $ | ||
Revenue | 3,382,970 | 5,005,691 | |
Cost revenue | 1,707,793 | 2,460,675 | |
Gross profit | 1,675,177 | 2,545,016 | |
Operating expenses | |||
Technology and development | 820,640 | 1,444,772 | |
Sales and marketing | 458,216 | 777,432 | |
General and administrative | 1,790,952 | 1,899,438 | |
Share-based compensation | 141,090 | 308,303 | |
Depreciation of property and equipment | 1,470 | 3,579 | |
3,212,368 | 4,433,524 | ||
Other expenses (income) | |||
Interest on lease obligations | - | 21,563 | |
Interest and accretion expense | 543,324 | 347,423 | |
Finance charges | 239,689 | 231,966 | |
Foreign exchange (gain) loss | (30,749) | 54,093 | |
(Gain) Loss on settlement of related party payable | 9,797 | (7,203) | |
Amortization of deferred finance charges | 85,900 | 67,790 | |
847,961 | 715,632 | ||
Net loss and comprehensive loss | (2,385,152) | (2,604,140) | |
Loss per share | |||
Basic and diluted loss per share | (0.01) | (0.02) | |
Weighted average number of shares outstanding | |||
Basic and diluted | 168,425,358 | 141,046,080 | |
Newtopia Inc.
Condensed Interim Statements of Cash Flows (Unaudited)
Six Months Ended June 30, 2024
(Expressed in Canadian Dollars)
Six Months Ended | ||||
2024 | 2023 | |||
Cash flows used in operating activities | ||||
Net loss and comprehensive loss | (2,385,152) | (2,604,140) | ||
Items not involving cash | ||||
Depreciation of property and equipment | 1,470 | 3,579 | ||
Amortization of intangible asset | - | 413,028 | ||
Amortization of deferred finance charge | 85,900 | 67,790 | ||
Debenture interest and accretion expense | 323,665 | 252,648 | ||
Interest on lease obligations | - | 21,563 | ||
Share-based compensation | 141,090 | 308,303 | ||
(Gain) Loss on settlement of related party payable |
9,797 |
(7,203) | ||
(1,823,230) | (1,544,432) | |||
Change in non-cash working capital | ||||
Trade and other receivables | 970,783 | 37,266 | ||
Prepaid expenses and deposits |
(152,975) |
(53,322) | ||
Inventories |
(41,036) |
185,395 | ||
Trade and other payables |
398,516 |
(10,602) | ||
Deferred revenue |
(48,185) |
- | ||
Contract asset/liability |
255,028 |
270,100 | ||
(441,099) | (1,115,595) | |||
Cash flows used in investing activities | ||||
Purchase of property and equipment |
- | (1,099) | ||
- | (1,099) | |||
Cash flows from financing activities | ||||
Credit facility withdrawals | 2,737,120 | 2,864,097 | ||
Credit facility repayments |
(2,758,323) |
(2,877,729) | ||
Credit facility financing costs |
(46,550) |
(29,160) | ||
Repayment of lease obligation |
- |
(357,186) | ||
Proceeds from private placement offering, net of costs |
641,440 |
1,467,295 | ||
573,687 | 1,067,317 | |||
Increase (decrease) in cash |
132,588 |
(49,377) | ||
Cash, beginning of period | 387,339 | 345,950 | ||
Cash, end of period | 519,927 | 296,573 | ||
View original content to download multimedia:https://www.prnewswire.com/news-releases/newtopia-reports-second-quarter-2024-financial-results-302218361.html
SOURCE Newtopia Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- BIOSAPIEN - THE REVOLUTIONARY CANCER PLATFORM DEVELOPER - NOMINATED AS "BEST STARTUP" IN THE 2026 PRIX GALIEN USA AWARDS
- FERRERO GROUP TO ACQUIRE PURELY ELIZABETH, A LEADING U.S. MODERN WELLNESS BRAND
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share